Get started
Author

Temeka Dawn Lewis-Wolfson

Observed name: Temeka Lewis-Wolfson
ORCID: 0000-0001-6608-652X
Observed ORCID: 0000-0001-6608-652X
OpenAlex ID: A5064057489
Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
2022 · Nancy Kierstin Reid, Kayla Rena Joyner, et al. · Annals of Pharmacotherapy · 15
120: Ciwa Versus Minds in Alcohol Withdrawal Syndrome: a Retrospective Cohort Analysis
2023 · Temeka Lewis-Wolfson, Maranda Switzer, et al. · Critical Care Medicine · 1
914: Evaluating Dosing of Midodrine for Acceleration of Weaning Norepinephrine in the Intensive Care Unit
2026 · Jacob Karr, Temeka Lewis-Wolfson, et al. · Critical Care Medicine
532: Addition of Remdesivir to Dual-therapy Dexamethasone and Baricitinib or Tocilizumab for Covid-19
2023 · Temeka Lewis-Wolfson, Jordan Mitchell, et al. · Critical Care Medicine
121: Addition of Phenobarbital to the Minds Protocol for Patients With Acute Aws in the Icu
2023 · Alexandria Lehman, Temeka Lewis-Wolfson, et al. · Critical Care Medicine
646: Onset of Dka During Delivery in a Pregnant Patient With Normal Glucose Tolerance Prior to Childbirth
2023 · Marcia Brackbill, Temeka Lewis-Wolfson, et al. · Critical Care Medicine
Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
2022 · Temeka Dawn Lewis-Wolfson, Kayla Rena Joyner · Annals of Pharmacotherapy
409: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe Covid-19
2022 · Temeka Lewis-Wolfson, Kayla Joyner, et al. · Critical Care Medicine
Works count: 8
Citation count: 16
H-index: 1
I10-index: 1
Year
Topic
Type